Huntington’s Disease Clinical Trials Update: September 2024
Mena Farag, Sarah J. Tabrizi, Edward J. Wild
Abstract
In this edition of the Huntington's Disease Clinical Trials Update, we expand on the ongoing extension study of PTC518 from PTC Therapeutics, including 12-month interim results from the parent study. We also discuss 24-month interim results from uniQure's AMT-130 program and 28-week follow-up results from Wave Life Sciences' SELECT-HD clinical trial of WVE-003. Additionally, we provide a comprehensive listing of all currently registered and ongoing clinical trials in Huntington's disease.
Topics & Concepts
Huntington's diseaseDiseaseClinical trialMedicineBioinformaticsBiologyInternal medicineGenetic Neurodegenerative Diseases